Breast cancer is a heterogeneous disease and its complexity has hindered the development of efficacious treatments targeting all breast cancer subtypes. Many studies have linked the diversity of breast carcinogenesis and metastasis to aberrant epigenetic signaling and control. Here, we focus on the current state of the discipline and review the major epigenetic enzymes controlling chromatin structure and function in the context of breast cancer, including (1) DNA methyltransferases, (2) lysine methyltransferases and demethylases, (3) protein arginine methyltransferases, and (4) histone acetyltransferases and deacetylases. Moreover, therapeutic drugs targeting these epigenetic enzymes are rapidly emerging and/or undergoing clinical trials. Therefore, we discuss the pharmacological manipulation of epigenetic enzymes for breast cancer treatment and present new clinical and survival outcome analysis on epigenetic factors that have evaded analysis to date. Understanding and pharmacologically exploiting epigenetic regulation in breast cancer promises to be an essential aspect of next-generation drug development and adjuvant therapies targeting advanced disease and treatment-resistant tumors. (Endocrinology 158: 431-447, 2017) 
B
reast cancer is one of the most common invasive cancers and causes of cancer-related death in women: It accounts for 25% to 30% of new cancers in women (1) . The incidence of breast cancer is increasing with improved life expectancy and the embracing of western lifestyles (1) (2) (3) . Importantly, breast cancer is a diverse and heterogeneous disease that has been classified into 18 to 21 subtypes displaying distinct histological, pathological, and molecular features as categorized by the World Health Organization (4) . Breast cancer is subgrouped into carcinoma in situ, including ductal, lobular, and invasive breast cancer, including invasive/infiltrating ductal and invasive lobular (4) .
Hormone-dependent breast cancer has been documented for .100 years. Measuring the expression of 2 nuclear receptors (NRs), the estrogen receptor (ER) and progesterone receptor (PR), has underpinned disease management, treatment, and prognosis (5) . For example, management of ER-positive cancer (ER+) includes therapy with ER antagonists, including selective ER modulators (e.g., tamoxifen). Treatment of postmenopausal women with ER+ cancer also involves aromatase inhibitors. For example, letrozole attenuates the conversion of androgenic hormones to estrogen. In addition to ER/PR status, human epidermal growth factor receptor 2 (HER2), also known as Erb-B2 receptor tyrosine kinase-2, is another marker of disease diagnosis and treatment (6) . HER2 overexpression in breast cancer can be treated with the monoclonal antibody trastuzumab and chemotherapeutic agents. Patients who are ER+/HER22 and resistant to hormone therapy may also respond to the second-line therapy with the class of ER antagonists denoted as selective ER degraders or downregulators. For example, fulvestrant drives proteasome-dependent ER decay (7) . In the context of advanced and metastatic ER+ breast cancer, clinical trials with pharmacological agents that attenuate cyclindependent kinase (CDK), phosphoinostol-3-kinase, vascular endothelial growth factor, type1 insulin-like growth factor receptor, and mammalian target of rapamycin have underscored the therapeutic utility of exploiting these signaling pathways. Furthermore, pharmacological inhibitors of these pathways have displayed improved clinical outcomes despite some adverse effects associated with acceptability of the medication (8) . Triplenegative breast cancer (TNBC; ER2/PR2/HER22) is notoriously resistant to hormonal therapy and is associated with poor clinical outcomes (9) . ER+, HER2+, and TNBC account for~70% to 75%,~15%, and~10% to 15%, respectively, of invasive breast cancer (10) .
The diversity and heterogeneity of the disease has driven further detailed molecular and cellular analyses and classification of subtypes (11) . Expression profiling and molecular footprinting of invasive breast cancers classified 5 tumor subtypes: luminal A and B, HER2+, and basal-like A and B (12) . Further analysis and subsequent refinement have identified new subtypes including (a) Claudin-low (defined by lack of differentiated luminal markers, increased expression of epithelialmesenchymal, mammary stem cell biomarkers, and immune response genes and include the TNBC subtype), (b) molecular apocrine subtype (ER2/AR+, and includes the TNBC and HER2+ subtypes), and (c) a novel luminallike subtype (ER2/HER22) (13) . However, current patient management is still limited to the histological analysis of ER/PR/HER2 status. Unfortunately, the genomic and transcriptomic profiling with next-generation sequencing and cell biological approaches to finely map subtypes has not yet reached the clinic and/or is not being adequately exploited (with the exception of a few comprehensive cancer centers focused on personalized medicine).
Existing therapies display adverse effects and inadequate efficacy, underscoring the need to identify new biomarkers, mechanisms, and causes of breast cancer. Importantly, genetic alterations are involved but do not provide a complete understanding of breast carcinogenesis, a clinically and biologically diverse disease. Currently,~15% of breast cancer cases are associated with family history or defined hereditary/ genetic mutations (14) , and up to 85% of neoplastic breast cancer occurs in women with no previous evidence of family history (14) .
In this context, emerging literature has indicated that other members of the NR-signaling superfamily, transcriptional coregulators and epigenetic modifications of chromatin, including methylation and acetylation status of DNA and histone/protein, play important roles in nonhereditary/nonfamilial breast cancer (15) . Several recent human studies have identified differential expression of the genes encoding the NR superfamily, epigenetic enzymes and transcriptional coregulators in neoplastic breast relative to normal breast tissue (16, 17) . The NR and coregulator signatures, including epigenetic enzymes, display discriminant, prognostic, and therapeutic use in predicting clinical outcomes in patient cohorts (17) .
This review focuses on the currently expansive and rapidly evolving field of "druggable" epigenetic enzymes that modulate the methylation and acetylation status of DNA and histones/proteins. These enzymes govern the epigenetic alterations that are important drivers of breast carcinogenesis, including proliferation, energetics, immortalization, angiogenesis, and invasion ( Fig. 1) . They are at the current interface of therapeutic and pharmacological exploitation by academic and industry-led research, and are important targets of adjuvant therapies in personalized medicine. This review does not address the epigenetic roles of histone serine phosphorylation, SUMOylation, glycosylation, biotinylation, ribosylation, proline/aspartate isomerization, and deimination (18) . Moreover, it does not discuss the rapidly evolving epigenetic roles of noncoding RNA (19) .
The term epigenetic regulation has been used to describe changes in genome function that transpire without an alteration in DNA sequence (20) . Epigenetic regulation chemically modifies the chromatin, resulting in Figure 1 . Alterations of epigenetic signaling in cancer that can activate key hallmarks of cancer pathways.
tissue-and organ-specific epigenomic phenotypes. Epigenetic modifications are driven by enzymes including the DNA methyltransferases (DNMTs), lysine methyltransferases (KMTs), lysine demethylases (KDMs), protein arginine methyltransferases (PRMTs), histone lysine acetyltransferases (HATs), and histone deacetylases (HDACs), which impact transcription and carcinogenesis in human health and disease (21) . Significantly, the therapeutic utility of epigenetic enzymes is underscored by the pharmacological tractability of histone and DNA methyltransferases, and histone deacetylases in drug discovery and the emergence of small molecule inhibitors (21) . For example, US Food and Drug Administration (FDA)-approved inhibitors of DNMTs and HDACs are now exploited as anticancer agents in the clinic (22) . Moreover, phase I/II clinical trials are underway with KMT inhibitors for the treatment of acute leukemia, and non-Hodgkin lymphoma (23) . In this context, we will address the role of epigenetic factors that control the DNA and protein modifications affecting the clinical outcomes associated with breast carcinogenesis.
DNMTs in Breast Carcinogenesis and Clinical Outcomes
DNA methylation is one of the most important epigenetic modifications that modulate the transcriptional process, and aberrant methylation of DNA has been implicated in breast carcinogenesis (24) . The methylation of DNA involves a covalent and reversible chemical modification of nucleic acid that is not associated with alterations in the DNA sequence (25) .
This central epigenomic process arises most frequently with the insertion of a methyl group, transferred from Sadenosyl methionine (SAM), at the carbon 5 position of the cytosine pyrimidine ring on genomic CpG sites [ Fig.  2(A) ]. Stirzaker and colleagues report, "There are over 28 million CpG sites in the human genome" and these CpG (E) High EZH2 expression is associated with adverse/poor survival in breast cancer. Prognostic z-scores from genomic profiles and clinical outcome of 16 breast cancer datasets were visualized using 4 color codes, (e.g., red represents a z-score .2, which is associated with poor survival outcome). TET, ten-eleven translocation.
dinucleotide islands do not appear at projected frequencies or dispersed consistently across the genome (26) . CpG islands are denoted as domains of .200 bases with .50% cytosine-guanine content. Approximately 60% of the regulatory domains of genes (particularly the transcriptional promoter regions) include CpG islands (27) . Interestingly, cell-, tissue-, and organ-specific gene silencing involves CpG shores (directly neighboring and flanking CpG islands) that are strongly conserved between rodents and humans (28) and associated with greater variation in DNA methylation. Recently, Edgar et al. (29) classified a new subset of islands, coined CpG ravines, that display a very consistent pattern of hypomethylation associated with hypermethylated flanking domains, active transcription, and housekeeping genes.
The methylation of DNA is mediated by the DNMT group of enzymes. The DNMT family includes 5 members-DNMT1, DNMT2, DNMT3A, DNMT3B, and DNMT3L-however, DNMT1, DNMT3A, and DNMT3B are the only members associated with methyltransferase activity (30) . Detailed reviews on the DNMT enzymatic machinery, addressing specific roles of the individual enzymes and association with human disease, including cancer, and therapeutic utility have been published and provide relevant background information (31, 32) .
Many studies have validated that dysfunctional DNA methylation is a hallmark of cancer. Mutations in the genes associated with all aspects of the DNA methylation machinery have been implicated in clinicopathological disease and many different cancers, including neoplastic breast cancer (33) . The expression of oncogenes and tumor suppressors in the process of breast carcinogenesis is effected by hypo-and hypermethylation.
In the context of breast cancer, aberrant epigenetic footprints, including DNA methylation status of several genes, have been identified in peripheral blood as potential breast cancer biomarkers (34) . Clark and colleagues (26) demonstrated the following: (a) ER2 breast cancer is associated with synchronized hypermethylation, and they classified TNBC into 3 unique methylation clusters associated with prognostic outcomes, with 17 differentially methylated regions identified as significantly correlated with survival outcomes; (b) an organized hypermethylation of key gene loci is associated with impaired binding of important transcriptional regulators and the initiation of breast cancer (35) ; and (c) the methylation state of enhancers is associated with ER+ breast cancer and therapeutic sensitivity (36) . For example, aberrant DNA methylation correlates with several clinical and pathological features of breast cancer, including TP53 status, tumor and histological stage, changes in gene expression, and prognosis (37) . In addition, hypermethylation of BRCA1 is associated with ER2 breast cancer and poor clinical outcomes (38) . Recently, it has been reported that DNA hypermethylation was associated with tumor hypoxia (39) . The study showed that tumor hypoxia decreases the demethylation activity of ten-eleven translocation enzyme [ Fig. 2(A) ], thereby inducing methylation at the promoters of tumor suppressors (39) .
To understand and explore the pathophysiological effects of these enzymes, we used the genomic profiles and clinical outcomes of 16 breast cancer datasets from Gentles et al. (40) and analyzed the effects of these epigenetic enzymes on survival outcomes with a statistical association, z-score (Fig. 2) . In doing so, we observed that all DNMT members are associated with poor or adverse survival outcomes, supporting the previously reported oncogenic role of DNMTs (Fig. 2) . We showed all prognostic values of these epigenetic enzymes in breast cancers to further facilitate future studies examining the therapeutic utility of epigenetic modulators for the development of efficacious treatments.
In terms of current therapeutic treatments and DNA methylation, DNMT inhibitors have been used in preclinical and clinical studies to evaluate their efficacy and utility in breast cancer (34) . Early compounds targeting DNMT1 that were FDA-approved for the treatment of leukemia and other hematological disorders showed promise but were limited by their stability due to inactivation by cytidine deaminase. The efficacy of this drug class (e.g., decitabine [5-aza-2'-deoxycytidine]) was dependent on strict patient selection and analysis of genetic signatures (Fig. 3) . The compound displayed utility in the attenuation of the invasive ability of ER2 cells, in contrast to accelerating aggressive characteristics of ER+ cells (41) . Moreover, treatment with this class of DNMT inhibitors is associated with loss of ER expression and development of therapeutic resistance. However, combination therapy with decitabine and the chemotherapeutic anthracyclines increased the efficacy of doxorubicin treatment in breast cancer cells (34) . Further studies demonstrated that the next generation of DNMT-inhibitor drugs, including zebularine, are associated with increased stability (Fig. 3) . The adverse effects include increased toxicity and reactivation of oncogenic genes and tumor suppressors. Further research is required to completely evaluate the utility of modulating DNA methylation for the treatment of breast cancer.
KMTs in Breast Carcinogenesis and Clinical Outcomes
Methylation of lysine residues on histones by KMTs has emerged as a target for the treatment of breast carcinogenesis. First identified in the 1960s, KMTs transfer methyl groups from SAM to lysine, affecting chromatin accessibility [ Fig. 2(B) ]. This group of enzymes contains the highly conserved 130 amino acid catalytic SET domain and the DOT1-like protein with no SET domain (42, 43) .
Lysine methylation occurs by transferring 1 to 3 methyl groups, resulting in mono, di-, and trimethylation (me1, me2, and me3, respectively; Fig. 2 ). Histone marks are associated with euchromatin accessibility and active transcription (e.g., H3K4me1-3, H3K9me1, H3K27me1, H3K36me3, H3K79me3, and H4K20me1) or related to transcriptional silencing (e.g., H3K9me3, H3K27me3, H3K56me3) (44) . In this review, we discuss and summarize the involvement of several KMTs in cancer and their therapeutic utility for the treatment of cancer.
Suppressor of variegation 3-9 homolog 1 (SUV39H1) generates H3K9me3, and is involved in breast carcinogenesis. In addition, SUV39H1 cooperates with an oncogenic factor, Snail1 to repress the expression of an adhesion molecule, E-cadherin (45) . Our survival analysis (Fig. 2) supports the observation that SUV39H1 functions as an oncogene (z-score, .2) in many breast cancer datasets (40) . The euchromatic histone methyltransferase-2 methylates H3K9, and is associated with elevated expression in lung cancer (46) . Studies have demonstrated that knocking down euchromatic histone methyltransferase-2 resulted in suppression of H3K9 methylation and inhibition of tumor cell migration or invasion (47) . Notably, our survival analysis demonstrated these enzymes are associated with poor survival in breast cancer (Fig. 2) .
Several KMT members, referred to as mixed-lineage leukemia (MLL), also play important roles in driving carcinogenesis and tumor initiation and invasion (48) . For example, KMT2B/ MLL2 is crucial for proliferation of HER2+ breast cancer and its expression reduces sensitivity to a HER2 inhibitor, lapatinib, that induces the FOXO tumor suppressor (49) . Furthermore, Kim et al. (50) showed that KMT2D/MLL4 expression is associated with poor survival in breast cancer and regulates tumor proliferation and invasiveness. We also observed in our survival analysis that these enzymes are associated with poor prognosis in breast cancer (Fig. 2) .
Methylation of H3K36 and H4K20 mediated by the nuclear receptor binding SET domain protein 1 (NSD1) has been shown to be related to diverse processes including alternative splicing, DNA damage repair, and DNA replication (51) . Furthermore, NSD1 expression has been linked to early tumorigenesis in many cancers (52) . Importantly, our analysis demonstrated that NSD1 is associated with poor survival outcomes in breast cancer (Fig. 2) .
SET and MYND domain-containing enzymes (SMYD) are involved in many cellular processes, including tumorigenesis and invasiveness. For example, SMYD3 is the specific methyltransferase for H3K4 methylation, a highly symbolic mark of active transcription, and is elevated in breast cancer tissue (53) . Small interfering RNA-mediated repression of SMYD3 significantly reduced growth of breast cancer cells and induced apoptosis (53) .
H3K79 is catalyzed by DOT1L histone methyltransferase (54) . Methylation of H3K79 has been implicated in cell cycle regulation and DNA damage response (54) . The disruption of this methylation can lead to cancers, making DOT1L a potential target for cancers such as leukemia (55) . More recently, DOT1L has been press.endocrine.org/journal/endoimplicated in the attenuation of proliferation, selfrenewal, and metastatic potential of breast cancer cells (56) , suggesting DOT1L inhibitors may have use as potential therapeutic agents in the treatment of breast cancer. Furthermore, the visualized z-score indicates that DOT1L is associated with poor survival (Fig. 2) , consistent with the therapeutic use of pharmacological agents that suppress its activity. Methylation of H3K27 is associated with transcriptional silencing, and is catalyzed by EZH2, a subunit of the polycomb repressive complex 2. EZH2 is found to be overexpressed in cancers (57, 58) ; in breast cancer tissues, the elevated levels of EZH2 correlated with poor prognosis, suggesting a link to the aggressive state of diseases and potential exploitation as a biomarker in breast cancer, as well as a possible target for treatment (57, 59 ).
The survival curve of EZH2 shows the oncogenic effect [ Fig. 2(E) ], using the Vijver dataset. EPZ-6438, a specific inhibitor of EZH2, is undergoing clinical trials in patients with B-cell non-Hodgkin lymphoma and advanced solid tumors (60) (Fig. 3) .
KDMs in Breast Carcinogenesis and Clinical Outcomes
Numerous studies and reports have provided evidence to demonstrate KDMs, which erase methyl groups from histone substrates [ Fig. 2(B) ], display prognostic and therapeutic roles in many different types of cancer (61) . This group of "eraser"-type enzymes deletes chemical covalent modifications from histone/protein substrates and includes 2 groups of the lysine-specific demethylase (LSD) families and the Jumonji C domain-containing histone demethylase (JHDM) families (61) (62) (63) (64) .
The LSD subgroup of KDMs that specifically target the mono-and dimethylated lysines are classified as the flavin adenine dinucleotide cofactor-dependent KDMs (i.e., flavin-containing amino oxidases). The group demethylates substrates through a flavin adenine dinucleotidedependent oxidative reaction, producing lysine and formaldehyde. The JHDM enzymes are larger, have the capacity to tridemethylate, and are enzymes that require ferrous iron and 2-oxoglurate/a-ketoglutarate substrates for catalytic activity, directing the release of demethylated lysine and formaldehyde (65) (66) (67) .
KDM enzymes target the mono, di-, and trimethylation of several lysine residues found on histone 3 (H3), including H3K4me1-3, H3K9me1-3, H3K36me1-3, and H3K27me1-3. It should be noted that demethylation of trimethylated lysine is mediated by the JHDM enzymes (61, 67) . Methylation of H3K4, H3K36, and H3K79 usually correlates with gene activation, whereas methylation of H3K9, H3K27, and H3K56 associates with transcriptional silencing. It is important to note that nonhistone protein N-methylation and demethylation also occurs on DNA binding factors (e.g., p53, NF-kB, and nuclear hormone receptors) (68) (69) (70) .
In the context of breast cancer, mutation or overexpression of KDMs has been observed. Aberrant expression of this large, diverse group of enzymes is associated with poorer or improved clinical outcomes. The differential effects on survival are associated with the spatiotemporal-specific effects of KDMs on prooncogenic or tumor suppressor genes (71) . The KDM enzymes, discussed previously in this article, play important roles in overall survival outcomes and therapeutic sensitivity.
Recently, Cao et al. (72) demonstrated in breast cancer biopsy specimens significantly increased expression of KDM1A/LSD1 that correlated with HDAC5 expression. These epigenetic enzymes interact physically with HDAC5, stabilizing KDM1A in the regulation of cellular proliferation and migration. Our survival analysis showed that KDM1A is moderately associated with poor survival (Fig. 2) . KDM1B/LSD2 is overexpressed in invasive breast carcinoma, and KDM1B depletion results in elevated levels of H3K4me1-2. The knockdown of KDM1B showed improved sensitivity to the DNMT inhibitor 5-aza-deoxyxytidine and the derepression of the important NRs, ERa, PR, RAR, and other relevant genes associated with positive therapeutic responses (73) .
KDM2A/JHDM1A expression is elevated in breast cancer and associated with poor clinical outcomes (Fig.  2) . Molecular and cellular studies suggested KDM2A regulates NOTCH signaling and angiogenic pathways that induce tumor stemness and growth (74) . Similarly, the KDM2B/JHDM1B enzyme is necessary for mammary stem cell renewal, and its increased expression in TNBC is associated with increased rates of tumor relapse (75) .
KDM3A/JHDM2A/JMJD1A has been shown as a positive coregulator of ER activity (76) that catalyzes the demethylation of H3K9 associated with transcriptional repression, resulting in derepression and activation of genes involved in invasion and metastasis. Moreover, the demethylation of H3K37me1 on the proapoptotic transcription factor p53 results in chemotherapeutic resistance, whereas depletion of KDM3A expression reverses these carcinogenic effects (77) . In contrast, the study by Paolicchi et al. (61) showed the increased expression of KDM3B/JHDM2B/JMJD1B and KDM5A correlates with improved clinical outcomes and responses to chemotherapy. Accordingly, the prognostic z-score in our survival analysis indicated that KDM3B expression is protective against breast cancer (Fig. 2) .
KDM4A/JHDM3A/JMJD2A is a regulator of cancer cell growth and metastasis, which correlates with the progression of human breast cancer, and is associated with the attenuation of the tumor suppressor ARHI (78) . KDM4B/JHDM3B/JMJD2B modulates ERa transcription and expression in breast cancer cells and ER+ breast cancer, involving demethylation of H3K9me3 in the ER promoter coupled with GATA3 recruitment (79) (80) (81) . KDM4C/JHDM3C/JMJD2C expression correlates significantly with the genes driving metabolic alterations in breast cancer. The mechanism involves interaction between KDM4C and HIF1a, which is recruited to a subset of genes involved in metabolic remodeling and metastasis (82) . Interestingly, our survival analysis indicated these KDM4 members are associated with favorable prognosis in breast cancers (Fig. 2) .
The study by Paolicchi et al. (61) showed the increased expression of KDM5A/JARID1A correlates with improved clinical outcomes and responses to chemotherapy, which is consistent with the z-score analysis in Fig. 2 . Furthermore, KDM5B/JARID1B expression is increased in luminal breast cancer and associated with adverse clinical outcomes in patients with ER+ breast cancer. KDM5B functions as a critical modulator of gene expression programs associated with the luminal-specific phenotype. KDM5C/JARID1C is overexpressed in breast cancer, and its expression is significantly associated with metastasis. This demethylase modulates the status of H3K4 methylation in the breast cancer metastasis suppressor-1 (BRMS1) promoter that controls the expression of the BRMS1 to inhibit tumor progression. Accordingly, the expression of KDM5C and BRMS1 are inversely correlated in human breast cancer (83) .
Increased KDM6A/UTX expression is associated with poorer prognosis, derepression and activation of genetic programs inducing cell proliferation, luminal to basallike transition, and metastasis. Furthermore, the function of KDM6A correlates with the activity of the MLL4, and the increased expression of these epigenetic enzymes correlates with poor survival outcomes in breast cancer (50) . However, the prognostic value in Fig. 2 shows protective effect in breast cancer. Further studies are required to identify the specific effect of KDM6A in breast cancer. KDM6B/JMJD3 expression is also increased in invasive breast carcinomas, and the mechanism involves demethylation associated with increased SNAI1 expression mediating the epithelial-mesenchymal transition (EMT) (84) . Our survival analysis also shows KDM6B/JMJD3 is associated with poor survival outcomes in breast cancer (Fig. 2) .
KDM7A/JHDM1D is similar to KDM2 and targets H4K20me1, H3K9me2, and H3K927me2 (85, 86) . It drives the formation of transcriptionally permissive chromatin. KDM7A expression increases in a nutrient-dependent manner in cancer cells and decreases tumor growth by attenuating angiogenesis (87) . PHF8/ KDM7B/JHDM1F overexpression is associated with miR-21, and the inhibition of this tumor suppressor drives oncogenic tumor growth (88) . PHF2/KDM7C/ JHDM1E targets H3K9me2 to induce transcription and, interestingly, controls Sox9-dependent gene expression (89, 90 ). PHF2 appears to interact with p53 (91) and decreases H3K9me2 inhibitory marks on the target gene promoters of p53 in lung and breast cancer. Park et al. (86) suggest that PHF2 functions as a tumor suppressor and the combined use of the PHF2, p21, and p53 provides prognostic and chemotherapeutic sensitivity data (86) . Accordingly, we found that PHF8 is significantly associated with poor prognosis and clinical outcomes, but PHF2 is associated with improved survival in breast cancer (Fig. 2) .
KDM8/JMJD5 demethylates H3K36me2, is necessary for cell proliferation, and epigenetically modulates expression of the cell cycle inhibitor Cdkn1a (92) and cell cycle-dependent gene expression (93) , and interacts with p53 to attenuate its function (94) . Moreover, knockdown of KDM8 expression induced expression of p53 target genes and inhibited cell growth (94) .
In terms of therapeutic use in breast cancer, the KDM enzymes as discussed are amplified or overexpressed in breast and many other cancers, and are necessary for breast cancer growth and metastasis. These features, coupled with the druggable nature of this superfamily of enzymes and epigenetic regulators, have positioned the KDMs in the pharmacological and therapeutic landscape for breast cancer treatment (95, 96) . Drugs targeting KDM1A in rodents displayed utility against leukemia. However, adverse effects were reported, including increased anemia and thrombocytopenia (97) . Clinical trials are underway in the context of acute myeloid leukemia and small cell lung carcinoma (85, 98) . However, Cortez et al. (99) demonstrated that the KDM1 inhibitor pargyline, an FDA-approved drug for the treatment of depression, significantly decreased tumor size in ER+ xenografts and affected epigenetic marks. Moreover, the KDM1-specific inhibitor NCL-1 (100) demonstrated utility to resensitize treatment resistant ER+ tumors, reminiscent of resensitization of acute myeloid leukemia cells to all-trans retinoic acid after treatment with the KDM1A inhibitor tranylcypromine (101) (Fig. 3) .
Inhibitors of the KDM2-6 enzymes targeting the catalytic Jumonji C domains and other domains of these large enzymes are emerging. However, their use has only been confirmed in breast cancer cell viability and proliferation studies (96 press.endocrine.org/journal/endodiscussed data from the Discovery on Target 2014 meeting, and the company EpiTherapeutics (Copenhagen, Denmark) reported on a drug that specifically and selectively targeted KDM5, attenuated cell proliferation in cell lines derived from solid cancers, and displayed dose-dependent suppression of tumor growth in xenograft studies (98) . In summary, the KDM superfamily modulates chromatin accessibility, transcriptional status, and the control of tumor suppressor and oncogene expression in normal growth and aberrant cell proliferation. The role of these enzymes in multiprotein complexes, and the association between dysfunctional KDM expression and clinical outcomes in cancer suggest that the group of enzymes is an important target for the pharmacological manipulation of aberrant transcriptional activity in breast cancer. The number of human demethylases, coupled with the effects on pro-oncogenic and tumor suppressor genes or programs, and with their role in large, multicomponent enzyme complexes controlling chromatin function suggests a viable tract of evaluation and therapeutic use in several specific cancer subtypes.
PRMTs in Breast Carcinogenesis and Clinical Outcomes
PRMTs are a class of enzymes that transfer a methyl group from SAM to the guanidino nitrogen of arginine. PRMTs generate 3 arginine methylation forms: monomethylarginine (MMA), asymmetric dimethylarginine, and symmetric dimethylarginine (sDMA) (102) [Fig.  2(C) ]. Human PRMTs can be categorized into type I (PRMT1, PRMT2, PRMT3, CARM1/PRMT4, PRMT6, and PRMT8) and type II (PRMT5, PRMT7, and PRMT9). The PRMT family possesses highly conserved motifs (I, post I, II, and III) and an identical THW loop, but the SAM-binding catalytic core domain and b-barrel like domain are highly divergent in N-and C-terminal regions, indicating that PRMTs have several unique specificities to different substrates.
Many studies have demonstrated that PRMTs regulate a wide range of genetic programs and cellular processes including cell cycle, RNA splicing and differentiation (103) . Furthermore, a growing body of literature highlights that the expression of PRMTs is associated with carcinogenesis, tumor progression, and metastasis of breast cancer (104) . Although the consequence of lysine methylation is relatively well studied, the role of PRMT action in breast carcinogenesis and survival outcomes is poorly understood. Here, we provide a description of the clinical relevance of these PRMTs regarding breast cancer and clinical outcomes.
PRMT1 has been extensively studied in many fields. Its activity is responsible for a substantial percentage of methylated arginine residues and modulates a wide range of cell types (105) . Specifically, asymmetric dimethylation on the histone 4 (H4) arginine 3 residue (H4R3me2a) by PRMT1 is involved in transcriptional activation, thereby driving oncogenic pathways (106) . For example, Gao et al. (107) showed that PRMT1 can generate H4R3me2a on the promoter region of ZEB1, which plays a critical role in EMT. Furthermore, PRMT1 directly methylates the arginine residue (R260) of the DNA-binding domain of ER, implying the important role of PRMT1 in breast cancer (108) . With regard to isoforms, the expression of alternatively spliced PRMT1 is significantly altered in breast cancer and its unique N-terminal sequence influences the PRMT1 catalytic activity and substrate specificity (109) . Because PRMT1-dependent methylation appears to modulate many key cellular progresses, survival analysis was performed on data from patients with breast cancer and showed that low PRMT1v1 expression was associated with the increased probability of disease-free survival (110) . These studies indicate that PRMT1 plays a key role in tumorigenesis and clinical outcomes in breast cancer, suggesting that high PRMT1 expression is potentially associated with poor survival in breast cancer. Importantly, we observed the poor prognosis of PRMT1 (Fig. 2) , using data from .3,500 patients with breast cancer in the kmplot datasets (111) ( Table 1) .
PRMT2 also has been reported to be overexpressed in breast cancer (112) . Meyer et al. (113) demonstrated that PRMT2 interacts with many NRs, including ERa and ERb in vitro, indicating the importance of PRMT2 in breast cancer biology (113) . Furthermore, PRMT2 knockdown in mouse embryonic fibroblast (MEF) cells increased the E2F activity and S phase entry, suggesting that PRMT2 is an essential modulator for endogenous E2F activation and the cell cycle (114) . In addition, Oh et al. (115) demonstrated that PRMT2 has high hazard ratio scores in breast cancer survival, using several human cohorts. PRMT2-dependent gene expression profiling uncovered that PRMT2 is involved in cell-cycle checkpoint, DNA repair, and pan-cancer signatures including chromosomal instability (115) . Interestingly, the study found that PRMT2 expression is negatively correlated to the nuclear receptor RORg and further validated that the expression of RORg is protective against breast cancer (115) . Zhong et al. (116) also showed that the expression of PRMT2 and several splice variants (i.e., PRMT2-a, -b, -g) were induced in certain breast cancer cell lines and a breast cancer tissue cohort, suggesting the increased PRMT2 expression is potentially associated with breast tumorigenesis and aggressiveness. In addition, we found that increased PRMT2 expression correlates with poor survival in breast cancers ( Fig. 2; Table 1 ).
The role of PRMT3 in breast cancer is relatively unclear. The primary substrates of PRMT3 have been reported in cellular programs, but the influence of PRMT3 on breast cancer clinical outcomes has not been investigated. The study demonstrated that PRMT3 physically binds to the von Hippel-Lindau tumor suppressor, and its protein complex methylates the major tumor suppressor p53 (117) . Furthermore, PRMT3 also interacts with another tumor suppressor, DAL1, which has been reported to be downregulated in many cancers (118) . Furthermore, our analysis shows that PRMT3 expression is associated with poor survival, with a high hazard ratio score ( Fig. 2; Table 1 ). This suggests that PRMT3 might be an attractive target for further study in breast carcinogenesis.
Coactivator-associated arginine methyltransferase 1 (CARM1)/PRMT4 activity and mechanism of action in gene regulation have been well studied in the literature (119) . With regard to breast cancer, Wang et al. (120) demonstrated that CARM1 methylates the chromatinremodeling SWI/SNF core subunit, BAF155. The methylation of arginine 1064 residue of BAF155 is associated with breast cancer recurrence and metastasis in an important manner. This evidence indicates that CARM1 plays an important role in acquiring tumorigenic activity through BAF155. Accordingly, Habashy et al. (121) reported that CARM1 induced tumorigenic effects and its expression is associated with poor prognosis in breast cancer. We further observed that CARM1 expression is significantly associated with poor or adverse survival in many breast cancer datasets ( Fig. 2; Table 1 ). In terms of drug development, Sack et al. (122) also showed the possibility of CARM1 inhibition, using indole-and pyrazole-derived structures. Therefore, targeting this epigenetic enzyme with small molecules may provide pharmacological options against breast cancer.
PRMT5 is a type II enzyme that generates sDMA. The body of evidence on the oncogenic role of PRMT5 in breast cancer is growing rapidly. Li et al. (123) functionally demonstrated the tumorigenic role of PRMT5 in lymphomagenesis and demonstrated that PRMT5 expression induces several oncogenic drivers. In the context of breast cancer, PRMT5 has been shown to be involved in TGFb-WDR77 signaling, thereby inducing cancer cell invasion (124) . The study showed that PRMT5 interacts with the WDR77 complex to catalyze arginine methylation. In the acquisition of EMT via TGFb response, the epigenetic PRMT5-WDR77 activity is necessary for tumor invasion and metastasis. Furthermore, PRMT5 appears to modulate genome stability by methylating KLF4 (125) . Consequently, it blocks ubiquitylation of KLF4 by the von Hippel-Lindau tumor suppressor. As a result, arginine methylation of KLF4 via PRMT5 increases the level of KLF4 protein and elevates the probability of breast carcinogenesis. With respect to the role of PRMT5 in breast cancer clinical outcomes, we demonstrate that PRMT5 expression correlates with poor prognosis (Fig. 2; Table 1 ).
There is also emerging evidence on the oncogenic role of PRMT6 in breast cancer. Harrison et al. (126) demonstrated that PRMT6 activates gene expression in a hormone-dependent manner. The overexpression of PRMT6 is associated with several cancer types, including breast, cervix, prostate, and lung cancers, indicating that PRMT6 might play an important role in the onset, incidence, and metastasis of cancer (127) . Furthermore, Kleinschmidt et al. (128) showed that PRMT6 directly represses p21 Waf1/Cip1 expression by targeting the promoter region (129) . Furthermore, Dowhan et al. (130) identified PRMT6-dependent genes using the Affymetrix exon microarray (Santa Clara, CA) and demonstrated that the PRMT6-dependent signature influences longterm survival in patients with breast cancer (130) . These data suggest that PMRT6 functions as an oncogene (Table 1) in breast cancer cells; inhibiting PRMT6 activity with recently described small molecules (131) may show therapeutic promise for breast cancer. We found that kmplot analysis shows the oncogenic effect (HR, 1.27) of (132) . However, another report showed PRMT7 only produces MMA as a type III PRMT (133) . In terms of the functional role of PRMT7, it has been demonstrated that PRMT7 is highly expressed in breast cancer and induces EMT by inhibiting E-cadherin. Baldwin et al. (134) also showed that PRMT7 promotes a well-known metastasis mediator, matrix metalloproteinase 9 and induces breast cancer cell invasion. We show that PRMT7 is associated with poor survival in both RFS and distant metastasisfree survival (DMFS; Table 1 ), and z-score analysis indicated its oncogenic effect in breast cancer (Fig. 2) . These studies underscore the potential pharmacological utility of PRMT7 inhibition in breast cancer.
The role of PRMT8 in carcinogenesis, including breast cancer, has been poorly understood and there are many ongoing studies to elucidate the exact mechanism of PRMT8 action. One recent study from Hernandez and Dominko (135) identified a novel PRMT8 isoform in human dermal fibroblast cells and grade IV glioblastomas, and demonstrated the isoform is required for proliferation. In addition, we found that PRMT8 is associated with poor survival, using z-score analysis (Fig.  2) , but kmplot data show PRMT8 is protective against breast cancer (Table 1) . Clearly, PRMT8 is an interesting target for further study in breast cancer. However, more research is required to clarify its functional role.
PRMT9 has been recently reported as a type II methyltransferase (136) . Interestingly Yang et al. (137) showed that PRMT9 is a nonhistone methyltransferase. For example, it methylates the arginine 508 site of the alternative splicing factor SAP145. Given that alternative splicing is of paramount importance in the RNA processing, PRMT9 might play a key role in many cellular programs and cancer biology.
Histone Acetyltransferases in Breast Carcinogenesis and Clinical Outcomes
The acetylation state of the terminal «-amino group of specific lysine residues on histones (i.e., H2A, H2B, H3, and H4) has an important role in breast carcinogenesis. The acetylation and deacetylation of histones are dynamic processes controlled by histone acetyltransferases (HATs) and HDACs [ Fig. 2(D) ]. The acetylation state of the chromatin also leads to the structural modification of the nucleosome. Acetylated (or hyperacetylated) chromatin is in a relaxed confirmation and associated with active transcription. In contrast, deacetylated (or hypoacetylated) chromatin is condensed and supercoiled, and associated with transcriptional silencing (and, in the context of cancer, the inhibition of tumor suppressor genes).
Although HATs are emerging as key modulators in epigenetic regulation, the effects and consequences of HATs in breast cancer have not been fully understood. We found that many HATs display various survival effects. For example, GTF3C4 and NCOA3 expression is associated with poor prognosis, but KAT6B, KAT8, ELP3, and NCOA1 expression correlates with improved survival outcome in breast cancer (Fig. 2) . Therefore, it is apparent that further studies on the roles of these acetyltransferases are required. We discuss several HATs involved in breast carcinogenesis and their potential therapeutic utility.
CREBBP has been shown to mediate crosstalk between ER and NF-kB signaling pathways in breast cancer cells (138) , indicating the potential involvement of CREBBP in breast carcinogenesis. CREBBP interacts with p300 (EP300 protein) and functions as a transcriptional coactivator of BRCA1 (139) . Furthermore, p300 contributes to epigenetically induce EMT in breast metastasis, cooperating with a DOT1L-cMyc complex. The elevated level of p300-DOT1L-cMyc is associated with the acquisition of cancer stem cell-like properties in breast carcinogenesis, implying that p300 functions as a potential oncogene and influences clinical outcome of breast cancer.
KAT5 appears to be an important regulator of TWIST activity by acetylating at H3K73 and H3K76 of the GK-X-GK motif, resulting in inhibition of the interaction between BRD4 and TWIST, hence reducing the aggressiveness of basal-like breast cancer. This suggests that small molecules manipulating KAT5 acetyltransferase activity could be promising candidate drugs against breast tumorigenesis and metastasis (140) . Doung et al. (141) revealed that KAT7 is a novel cyclin E/CDK2 substrate, and coexpression of the low-molecular weight cyclin E and KAT7 induces aggressive cancer stem cell properties, opening a possibility of therapeutic utility in breast cancer. Furthermore, KAT7 has been shown to be involved in ER stability, and depletion of KAT7 induces repression of growth in breast cancer cells (141) .
HDACs in Breast Carcinogenesis and Clinical Outcomes
The dysfunctional balance between acetylation and deacetylation is clearly associated with human disease and tumorigenesis. In particular, aberrant expression and activity of HDACs (i.e., amidohydrolases that share a similar a catalytic core for acetyl-lysine hydrolysis) drive several forms of cancer (142) (143) (144) . Over the last decade, several reports have highlighted the age-dependent epigenetic changes in acetylation and methylation associated with breast cancer risk (145, 146) . The role of acetylation status has been highlighted in driving agerelated disease. Pharmaceutical attenuation of epigenetic enzymes is emerging as a treatment of age-dependent diseases, including cancer (146) .
HDACs deacetylate proteins, including DNA bindingtranscription factors and other integrators of cell signaling that are cellular signal transducers (e.g., cytokines, growth factors, TGFb, EGF, interferon, and wnt signaling). These nonhistone targets include NRs, E2F, p53, c-MYC, NF-kB, SMAD7, PTEN, b-catenin, STAT, GATA, and FOXO groups. Many nonhistone proteins affected by HDACs are pro-oncogenic and are critical drivers of the onset, incidence, progression, and metastasis of cancer (147) .
Sequence homology, subcellular location, and the features of the catalytic site have been used to classify the 18 members of the human HDAC family into 5 groups: class I HDACs (1) (2) (3) 8) , class IIa HDACs (4, 5, 7, 9) , class IIb HDACs (6, 10), class III HDACs (i.e., sirtuins 1 through 7, the zinc ion-independent/NAD+-dependent cell redox regulators), and class IV HDACs, composed of only HDAC11, which displays similarities to both class I and II (142) . Differential expression of HDACs has been significantly associated with increased and decreased overall and disease-free survival (RFS and DMFS) in breast cancer, and the use of HDAC inhibitors as adjuvant therapies is gaining traction (41, 148) .
Dysfunctional class I HDAC expression and activity have been associated with breast cancer (149) . The expression of the HDAC1 and HDAC3 correlated with NR (i.e., ER and PR) status in 200 patients with breast cancer, showing~40% immunoreactivity from all 200 patients. Interestingly, increased HDAC1 expression correlated with better overall survival and DMFS in ER+/PR+/HER22 but not in ER2/PR2 (or HER2+) breast cancer (149, 150) . Another study demonstrated that class I HDACs are differentially expressed with HDAC2 and HDAC3 expression, correlating with aggressive cancer tumor subtypes (e. g., ER2/PR2). HDAC2 expression was significantly associated with HER2+ breast cancers (149) . These reports are consistent with our survival analysis of HDAC2 in breast cancer, showing its oncogenic effect (Fig. 2) .
Increased expression of Class IIa HDACs is associated with decreased survival in ER+ breast cancers (149) . Class IIa HDACs attenuate the MEF2-dependent transcriptional signature associated with differentiation and apoptosis. The poorer clinical outcomes are associated with the repression of the MEF2-dependent proapoptotic NR NR4A1/Nur77 (151) . HDAC inhibitors increase NR4A1 expression in ER+ breast cancer cells (151) . In the context of class IIa HDACs, the attenuation of HDAC5 expression suppresses cell growth and metastasis (152) . HDAC9 is overexpressed in the basal subtype of breast cancers and is associated with poor prognosis and SOX9 expression (153) . SOX9 silencing significantly reduces HDAC9 expression (153) . The class IIb HDAC6 expression correlated with ER+/PR+ and low-grade breast cancer, and diseasefree survival (154) .
In the context of HDAC inhibitors and therapeutic treatment, an increasing number of studies on the clinical relevance of HDACs and the therapeutic potential of HDAC inhibitors have been reported. HDAC inhibitors can generally be classified into hydroximates, cyclic peptides, aliphatic acids, and benzamides (155) , and grouped according to their specificity (e.g., zinc dependent [HDAC classes I, II, and IV] and zinc independent [class III]) (156) . Due to high conservation of the enzymatic region between members of classes I and II HDACs, HDAC inhibitors activities are usually not selective and can inhibit at least several members of the family. Therefore, HDAC inhibitors can confer a wide range of effects on cancer cells, such as differentiation, apoptosis, cell cycle arrest, DNA repair, and autophagy (155) With many clinical trials conducted and ongoing, 4 HDAC inhibitors-vorinostat (or SAHA) (157), romidepsin (FK228) (158) , belinostat (159) , and panobinostat (LBH0589) (160)-have been approved for clinical treatment in patients with cancer, mainly targeting cutaneous T-cell lymphoma and multiple melanoma.
The anticancer effects of these molecules have not produced favorable and expected outcomes in solid tumors. Many preclinical and clinical studies have evaluated the use of HDAC inhibitors in the treatment of cancer with solid tumors, including breast cancer either alone or in combination with hormonal treatments (161) . The use of vorinostat was evaluated in a small patient cohort with metastatic breast cancer in a phase II trial (162) . No response or stabilization of tumor was observed in this study. Entinostat (MS-275), a benzamide with high specificity for the class I HDACs, is currently in a phase II/III trial for advanced ER+ breast cancer (163) . In this randomized, double-blinded trial of 130 patients already receiving exemestane (an aromatase inhibitor), treatment was administered with either entinostat or placebo. Improved clinical outcomes were observed in a subset of patients, demonstrating the possibility of an HDAC inhibitor as an additional drug in the treatment of breast cancer (163) . In another recent phase II clinical study, patients with ER+ breast tumors were administered a combination treatment of the HDAC inhibitor vorinostat and tamoxifen; 40% of the patients on the combined treatment showed tumor regression and reversed hormone resistance (164) . ER+ breast cancer cells were redirected into apoptosis with HDAC inhibitor doi: 10.1210/en.2016-1716 press.endocrine.org/journal/endotreatment (164, 165) . Studies have also shown ER transcriptional activity with re-expression of ER after treatment with an HDAC inhibitor, providing sensitivity to tamoxifen and reversing the resistance to hormone therapy (166) , mediated through inhibition of HDAC2 (167) . Vorinostat was also investigated in patients with metastatic breast cancer in another phase I/II clinical trial in combination with paclitaxel and bevacizumab (168) . HDAC inhibitors have shown convincing evidence with increased antitumor effects in combination therapy in various clinical trials in breast cancer (169) . Treatments with HDAC inhibitors alone have either minimal or no response in patients with cancer (161) . Further studies and trials on bioavailability and toxicity will be required; in addition, understanding the molecular mechanisms of HDAC inhibition and its targets in breast tumors will improve better prediction of response to treatments.
Summary and Conclusion
Breast cancer epigenetics is a field of ongoing research that continues to empower our knowledge of the heterogeneity and pathophysiological signaling in breast cancer. The advances in sequencing technology have led to the identification of precise molecular functions and epigenetic mechanisms in a complex pattern of breast cancer. However, further investigations are required to uncover the dysregulation of epigenetic programs and the crosstalk with the other relevant pathways in breast carcinogenesis. To improve prognosis and develop more effective drug treatments for patients with breast cancer, we expect comprehensive research and drug development targeting the activity of epigenetic enzymes to be of paramount importance. This rapidly emerging discipline provides the promise of improved clinical outcomes and real changes to survival rates that decrease the probability of tumor relapse and metastasis. In conclusion, emerging studies and further investigation of epigenetic signaling coupled with the development of therapeutic compounds will lead to crucial advances in pharmacological treatment of breast cancer.
